Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Tuesday, 14 July 2009
Coventry University Podcasts » Blog Archive » One woman, a multinational and a victory - Shelley Jofre, Panorama
Panorama reporter Shelley Jofre discusses her investigated allegations that psychiatric drugs, in particular the best-selling antidepressent Seroxat have devestating side effects and are being over-prescribed to children in the UK and US. Shelly questions how much faith we should put in the medicines we take
http://www1.coventry.ac.uk/podcasts
Ernest Venn

Sarah Venn's father posts on BBC Panorama site - but no mention that he co-wrote/modified Healy's original withdrawal protocol

I have just watched the third series of Panorama addressing the very serious problems of patients taking Seroxat. I commend the production team for an excellent and balanced view that has hitherto been kept secret by GSKB.
I am Sarah Venn's father and I cried when watching the programme. I felt for the families of those who have lost loved ones. I have nursed and watched my daughter attempt to withdraw from Seroxat only to be there when she failed after 12 months of effort that you or I would have given up after one week. GSKB have only one interest - to make money.
Dr Benbow is a highly paid executive of GSK who only cares about his wealth, not the interests of the public who are prescribed the drugs the company he works for make. I was appalled to listen to Prof Sir Alasdair justify his position in not controlling the drugs agency. For me he should be sacked, not allowed to resign, and his knighthood taken away. I am a saddened father but thankful to your programme for bringing this very important topic to the attention of the people. Ernest Venn, England
Monday, 13 July 2009
Bob Fiddaman considers himself worse off than the mother & her two hour old dead baby
Cyndi only a vile and nasty person would use such posts to paint themselves as 'victim' ........
from Bob's fiddaman.blogspot.com
because she was taking Effexor not Seroxat - this was Bob Fiddamans response!
He considers himself worse off than the mother - more important than a two hour old dead baby.
This is the sort of person you choose to believe - the sort of person you're supporting!!
Tues http://groups.yahoo.com/group/uksurvivors/message/45883
Dr Hart said "We have all done things on these medications we are not proud of" - check out Phillip Carmichael who took dostinex
Fidders, mate, let it go... I warned you about getting drawn in
Radagast said
Fidders, mate, let it go... I warned you about getting drawn into their reality.I know it's difficult not to respond, when you see an accusation levelled against you, but just roll with it, man. Stick up a link to Mardi's blog, give her a bit of publicity, and leave it at that.You're spending valuable time and effort on something that doesn't really impact you, at all. Take a step back, get a new perspective, see the ridiculousness of it, laugh, and then get on with something more productive.Matt
https://www.blogger.com/comment.g?blogID=10459981&postID=628606919444050694
Sunday, 12 July 2009
Real purpose of Fiddaman / MHRA meeting, at request of MHRA, was to discuss their window dressing Patient and Public Engagement Strategy

Will Bob Fiddaman write about all the liquid SSRI's or just continue his fishing trip for Mark Harvey? Don't hold your breath!
Will Bob Fiddaman write to the MHRA about the equally vague choice of words in Escitalopram liquid PIL?

Please note
Some patients with manic-depressive illness may enter into a manic phase. This is characterized by unusual and rapidly changing ideas, inappropriate happiness and excessive physical activity. If you experience this, contact your doctor.
Symptoms such as restlessness or difficulty in sitting or standing still can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.
Seroxat Patient Information Leaflet - Vague. OOPS looks like the Prozac one is equally vague !!

Like all medicines, Prozac can cause side effects, although not everybody gets them.
• If you get a rash or allergic reaction such as itching, swollen lips/tongue or
wheezing/shortness of breath, stop taking the medicine straight away and tell your
doctor immediately.
• If you feel restless and cannot sit or stand still, you may have akathisia; increasing your
dose of Prozac may make you feel worse. If you feel like this, contact your doctor.
• Tell your doctor immediately if your skin starts to turn red or you develop a varied skin
reaction or your skin starts to blister or peel. This is very rare.
Saturday, 11 July 2009
MHRA says Efexor is an SSRI, Biol Psychiatry says Seroxat is an SNRI whilst Archives of Pharmacology says SDRI
Meanwhile chief manipulator Mark Harvey has to proove - Seroxat an SSRI, an SNRI or even an SDRI, you decide? Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex
AbstractParoxetine, a selective serotonin (5-HT) reuptake inhibitor, increased extracellular 5-HT and dopamine levels, as determined by microdialysis, in the medial prefrontal cortex (mPFC) of freely moving rats. There was a difference in the time course of the maximum response between the 5-HT and dopamine levels after paroxetine administration. The extracellular dopamine concentration reached its maximum 20 min after the peak effect of 5-HT had appeared. The paroxetine-induced increase in extracellular dopamine concentration, but not 5-HT concentration, was inhibited by the 5-HT3-receptor antagonist granisetron. These results suggest that the increase in extracellular dopamine concentration in the mPFC elicited by paroxetine is the result of stimulation of 5-HT3 receptors by the extracellular accumulation of 5-HT in the mPFC
What are we going to do now Fidders - the MHRA says Efexor is an SSRI & Biol Psychiatry says Seroxat is an SNRI?

Then again… he’s more than happy trying to prove himself right when it’s abundantly clear that he is so so wrong.
Seroxat an SSRI or an SNRI you decide ? - Paroxetine binding to the rat norepinephrine transporter in vivo
BACKGROUND: The norepinephrine transporter (NET)/uptake site is an antidepressant-sensitive transporter located on plasma membranes of noradrenergic neurons and other specialized cells that remove norepinephrine (NE) from the synapse to terminate the actions of NE. The antidepressant paroxetine is believed to produce its therapeutic effects primarily by acting as a highly selective antagonist of the serotonin transporter (SERT). However, in vitro data indicates that paroxetine inhibits the NET. The present study was designed to determine whether paroxetine inhibits in NET in vivo. METHODS: Rats were administered paroxetine (6.5, 10.0, or 15.0 mg/kg/day) via osmotic minipumps for 1 week. Following attainment of steady state serum concentrations, cortical NET function was assessed by both [3H]-nisoxetine binding and [3H]-norepinephrine uptake assays conducted ex vivo. RESULTS: In unwashed brain homogenates, serum paroxetine concentrations greater than 100 ng/mL were positively correlated with the observed Kd for [3H]-nisoxetine. At [3H]-nisoxetine concentrations associated with 50% transporter occupancy in vehicle treated rats, [3H]-nisoxetine binding was decreased 21% and 34% in rats exhibiting serum paroxetine concentrations > 100 ng/mL and > 500 ng/mL, respectively. CONCLUSIONS: Although paroxetine is a very potent inhibitor of the SERT, paroxetine also inhibits the NET at serum concentrations > 100 ng/mL. This novel finding may underlie the broad therapeutic utility of paroxetine in mood and anxiety disorders.
Seroxat case Press release from Mark Harvey who forgets to tell us that SSRI Efexor is harder to get off than Seroxat
Lymm woman to sue firm for £50k
8:00am Friday 10th July 2009
Comments (0) Have your say »
By Joanna Lean »
A WOMAN from Lymm has launched a legal battle against pharmaceutical giant GlaxoSmithKline.
Jennifer Kulczycki, of Linden Close, is seeking up for £50,000 for personal injuries and other losses suffered while taking Seroxat, a drug licensed to treat symptoms of depression.
She has been taking it for nine years and is one of more than 600 people taking legal action under the Consumer Protection Act 1987.
The claimants all allege difficulties in withdrawing from the drug. Since Seroxat was first prescribed it has been linked to the suicides of around 50 people and was banned for under 18s after reports that it trebled the risk of suicidal thoughts in depressed children.
The cases against GSK are due to be heard in autumn 2010.
In a previous statment GSK said: “Seroxat has benefited millions of people worldwide. We believe the product is not defective and there is therefore no merit in this litigation.”
A spokesman for the Seroxat User Group said it had heard from more than 40,000 people all suffering with side effects and withdrawal problems.
Many have problems when it comes to stopping taking the drug, with sickness, anxiety and aggression all common complaints during withdrawal.
“The drug companies make lots of money and never think about the people affected,” the spokesman said.
The group wants Seroxat to be more commonly prescribed in a liquid form to help people trying to stop taking the drug.
Mark Harvey, of law firm Hugh James, who is representing Miss Kulczycki said: “When patients took the drug, not only was there no warning of withdrawal problems, there was also a statement on the data sheet until about 2003 which said you cannot be addicted to Seroxat.
“Unfortunately, many people are having difficulties as they try to withdraw from the drug. There are a few who have not been able to stop taking it.”
Last March the Medicines and Healthcare products Regulatory Agency (MHRA) concluded a four-year investigation into GSK and Seroxat, focusing on whether the company had failed to disclose information about the safety of Seroxat for under 18s.
The agency ruled that there was no realistic prospect of a conviction because legislation at the time was not strong enough to require companies to tell regulators of safety information.
Meeting with Fiddy last September - yes you guessed it we were just playing him, thats what we do. We don't regulate all SSRI's we play games with SUG
DAVID HEALY **NEW WITHDRAWAL PROTOCOL
Last September I met with the MHRA and asked them if they would be prepared to meet with David Healy to discuss the serious withdrawal issue regarding SSRi's.I'm pleased to announce that David has now met with them and laid a new, revised withdrawal protocol on the table.As I understand, notes were taken at the meeting and should be available soon.Hopefully, the MHRA will now have a better understanding of the struggles people have when withdrawing from SSRi's.The new withdrawal protocol can be downloaded here.
Fid
Dr Healy's new withdrawal protocol - "not within our remit as the MHRA to endorse guidelines for the clinical management of patients"

Choice is yours.
You a coward like your bullying, pervert friend or you prepared to answer the above"
“I think that I am familiar with the fact that you are going to ignore this particular problem until it swims up and BITES YOU ON THE ASS!” – Matt Hooper – JAWS
"ON THE ASS!" - Matt Hooper - JAWS
http://groups.yahoo.com/group/uksurvivors/message/44782

